ClearPoint Neuro, Inc. Common Stock
CLPTClearPoint Neuro, Inc. (CLPT) specializes in neurodiagnostic and neurosurgical technologies, focusing on delivering precision-guided solutions for minimally invasive brain treatments. The company's systems are used for procedures such as deep brain stimulation, biopsies, and drug delivery, aiming to improve patient outcomes through advanced neuro-navigation and imaging techniques.
Company News
The global MRI-guided neurosurgical ablation market is expected to grow significantly, reaching a value of USD 227.56 million by 2034, driven by advancements in technology, regulatory approvals, and enhanced healthcare accessibility.
ClearPoint® Navigation System to be used for all enrolled patients in Aspen's ASPIRO Parkinson's cell therapy clinical trial
ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.
Newly Launched ClearPoint Neuro technology - SmartFrame OR and Prism Laser will be on display at ASSFN in Nashville from June 1 - 4
The consensus price target hints at an 81.5% upside potential for ClearPoint Neuro (CLPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
